FOR IMMEDIATE RELEASE
Edwin Kwok & Co (“EKC”) is pleased to announce its role as Hong Kong and U.S legal counsel to RemeGen Co., Ltd. (“RemeGen”; 688331.SH/09995.HK) in its recent placement of 19,000,000 new H shares, raising approximately US$103 million in gross proceeds.
On 22 May 2025, RemeGen entered into a placing agreement with Morgan Stanley Asia Limited and Huatai Financial Holdings (Hong Kong) Limited. The placing shares represent approximately 10.02% of RemeGen’s existing issued H shares and approximately 3.49% of its total issued shares.
The net proceeds from the placement will be used to support the further development of RemeGen’s core product Telitacicept (RC18), particularly for key indications such as Myasthenia Gravis and Membranous Nephropathy.
EKC team is led by Founder and Managing Partner, Edwin Kwok, and includes our partner Iris Leung, consultants Lillian Cheung and Yuki Tsang. “We are honoured to support RemeGen in this important transaction,” said Edwin Kwok. “RemeGen is a standout innovator in the biotech sector, and our team is committed to providing seamless legal support for complex cross-border capital markets matters.”
Edwin Kwok & Co focuses on a full range of corporate, capital markets, mergers and acquisitions, private equity, and regulatory matters. With combined U.S., Hong Kong and English law capabilities, we provide integrated, comprehensive and innovative solutions on a wide variety of matters globally.
Contact:
Edwin Kwok & Co
admin@ekwokco.com
